Publications by authors named "Kentaro Yumoto"

Community-acquired pneumonia (CAP) is associated with high mortality rates and often results in prolonged hospital stays. The potential of machine learning to enhance prediction accuracy in this context is significant, yet clinicians often lack the programming skills required for effective data mining. This study aimed to assess the effectiveness of a low-code approach for assisting clinicians with data mining for mortality and length of stay (LOS) prediction in patients with CAP.

View Article and Find Full Text PDF

Introduction: Total baseline tumor size (BTS) is a prognostic factor for programmed death 1 and programmed death-ligand 1 (PD-L1) inhibitor treatments. However, the prognostic value of total BTS for patients with small-cell lung cancer (SCLC) who receive chemotherapy plus PD-L1 inhibitor remains unknown. Thus, in this study, we aimed to determine whether total BTS is associated with prognosis in patients with SCLC who receive chemotherapy plus PD-L1 inhibitor as first-line therapy.

View Article and Find Full Text PDF

Diagnosis and treatment of pulmonary hypertension (PH) in patients with lung diseases (PH-LD) remain unestablished and pose significant challenges. In this report, we present a case of a 77-year-old patient with an indeterminate for usual interstitial pneumonia pattern along with chronic obstructive pulmonary disease, who developed groups 1 and 3 PH. Following diagnosis, upfront triple oral combination therapy (UTOCT) with macitentan, sildenafil, and selexipag was initiated.

View Article and Find Full Text PDF
Article Synopsis
  • This study examined the effectiveness of two treatment combinations for advanced non-small cell lung cancer (NSCLC): pembrolizumab plus chemotherapy (CP) and nivolumab plus ipilimumab and chemotherapy (CNI).
  • It was conducted with 182 patients and aimed to assess overall survival (OS), progression-free survival (PFS), response rates, and safety profiles of each regimen.
  • The results indicated that CP offered better PFS (11.7 months) compared to CNI (6.6 months), while there were no major differences in OS, suggesting that CP may be a preferable first-line therapy in real-world settings.
View Article and Find Full Text PDF

Inflammatory endobronchial polyps (IEPs) are rare, benign bronchial tumors posing diagnostic and therapeutic challenges owing to limited data. A 55-year-old man, receiving treatment for allergic bronchopulmonary aspergillosis, presented with a one-week history of fever and purulent sputum. Diagnosed with pneumonia, he received antimicrobial treatment.

View Article and Find Full Text PDF
Article Synopsis
  • Bronchial thermoplasty (BT) is a treatment for severe asthma that can reduce asthma attacks, emergency visits, and hospitalizations, but the factors affecting its effectiveness are not well understood.
  • In a study involving 20 patients, it was found that 30% achieved clinical remission post-BT, with a lower asthma control test (ACT) score predictive of success; those with remission had an ACT score of 11 compared to 15 for those without.
  • This research suggests that younger adults with severe asthma and a specific range of lung function prior to BT may benefit more, indicating the potential for pre-treatment assessments to guide BT outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the effects of new systemic therapies on non-small-cell lung cancer (NSCLC), focusing on gene mutations and PD-L1 levels.
  • Conducted in Japan with 863 NSCLC patients, researchers compared various treatments and analyzed survival rates based on therapy type and PD-L1 expression.
  • Results highlighted that targeted therapies led to the best overall survival and emphasized the importance of incorporating molecular diagnostics and PD-L1 assessment in treatment plans.
View Article and Find Full Text PDF
Article Synopsis
  • Patients with EGFR mutated non-small-cell lung cancer experience shorter survival if their EGFR-TKI therapy is interrupted due to interstitial lung disease (ILD), but previous studies suggest that continuing the treatment might improve overall survival.* -
  • This study analyzed data from 690 patients to evaluate the safety and success rates of restarting EGFR-TKIs after they developed ILD, finding that 40.2% of patients resumed treatment and 81.9% of them had successful outcomes.* -
  • While the initial rate of EGFR-TKI-induced ILD was notable at 13.6%, the promising success rate of readministration suggests that it could be a feasible option for managing this type of lung cancer.*
View Article and Find Full Text PDF

Emphysema, a type of lung-destroying condition associated with chronic obstructive pulmonary disease (COPD), is an inflammatory lung disease mainly due to cigarette smoke exposure. As there is no curative therapy, prevention should be considered first by cessation of smoking to avoid exposure to oxidative stresses and inflammatory mediators. In addition, therapies involving antioxidative and/or anti-inflammatory agents such as heme oxygenase (HO)-1 are candidate treatments.

View Article and Find Full Text PDF